{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T20:12:54Z","timestamp":1794514374605,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medicines and Healthcare products Regulatory Agency, United Kingdom","id":[{"id":"https:\/\/ror.org\/05fan1e59","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/H009485\/1"],"award-info":[{"award-number":["BB\/H009485\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/H009485\/1"],"award-info":[{"award-number":["BB\/H009485\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Several\n                    <jats:italic>Bunyavirales<\/jats:italic>\n                    families have been listed as being of high pandemic or epidemic risk by the WHO R&amp;D Blueprint. To support pandemic preparedness and the 100 Days Mission, along with rapid provision of vaccines and therapeutics, the development of tools to assess the immune response is required. Pseudotyped viruses (PV) have been shown to be a suitable alternative to authentic infectious virus to measure virus-neutralising activity, a key component of the immune response. They alleviate the need to acquire and amplify viral isolates and do not require high containment facilities. Generating PV of some families within the class\n                    <jats:italic>Bunyaviricetes<\/jats:italic>\n                    is challenging because of a lack of co-localisation of viral glycoproteins at the vector budding site. Here, we describe a versatile plug-and-play system focusing on two prototype viruses for the family\n                    <jats:italic>Phenuiviridae<\/jats:italic>\n                    , Rift Valley fever virus (RVFV) and for the family\n                    <jats:italic>Nairoviridae<\/jats:italic>\n                    , Crimean-Congo haemorrhagic fever virus (CCHFV). Shared key parameters for the production of RVFV and CCHFV PV were identified and optimised on a single-cycle, recombinant vesicular stomatitis virus vector (VSV), which allowed for the successful and rapid production of PV for Dabie bandavirus and Oropouche virus. We propose that this system could be successfully applied to other high-consequence bunyaviruses, including those yet unknown, which may emerge in the future. Assessment of the novel bunyavirus PV generated here demonstrated a good correlation with traditional neutralisation assays with infectious virus. This system offers an adaptable and widely accessible platform that can be rapidly developed in response to emerging viral threats.\n                  <\/jats:p>","DOI":"10.1038\/s41541-025-01278-8","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:19:25Z","timestamp":1762431565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A system to rapidly develop a bunyavirus pseudotyped virus neutralisation assay for pandemic preparedness"],"prefix":"10.1038","volume":"10","author":[{"given":"Federica","family":"Marchesin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Mutuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Jeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryson","family":"Ndenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kempster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart D.","family":"Dowall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Almond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley C.","family":"Banyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Buczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazif","family":"Elaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mirazimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hewson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Mattiuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"1278_CR1","unstructured":"WHO. Emergencies: International health regulations and emergency committees. https:\/\/web.archive.org\/web\/20210815072835\/https:\/\/www.who.int\/news-room\/q-a-detail\/emergencies-international-health-regulations-and-emergency-committees (2019)."},{"key":"1278_CR2","unstructured":"Pandemic Prepardness Partnership. 100 Days Mission. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/992762\/100_Days_Mission_to_respond_to_future_pandemic_threats__3_.pdf (2021)."},{"key":"1278_CR3","unstructured":"WHO. Pathogens Prioritization: a Scientific Framework for Epidemic and Pandemic Research Preparedness. https:\/\/cdn.who.int\/media\/docs\/default-source\/consultation-rdb\/prioritization-pathogens-v6final.pdf?sfvrsn=c98effa7_7&download=true (2024)."},{"key":"1278_CR4","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1016\/j.vaccine.2015.04.071","volume":"33","author":"EM Bentley","year":"2015","unstructured":"Bentley, E. M., Mather, S. T. & Temperton, N. J. The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination. Vaccine 33, 2955\u20132962 (2015).","journal-title":"Vaccine"},{"key":"1278_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/v13020217","volume":"13","author":"K Toon","year":"2021","unstructured":"Toon, K., Bentley, E. M. & Mattiuzzo, G. More than just gene therapy vectors: lentiviral vector pseudotypes for serological investigation. Viruses 13, 217 (2021).","journal-title":"Viruses"},{"key":"1278_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","volume":"169","author":"MA Whitt","year":"2010","unstructured":"Whitt, M. A. Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365\u2013374 (2010).","journal-title":"J. Virol. Methods"},{"key":"1278_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3389\/fimmu.2015.00161","volume":"6","author":"GW Carnell","year":"2015","unstructured":"Carnell, G. W., Ferrara, F., Grehan, K., Thompson, C. P. & Temperton, N. J. Pseudotype-based neutralization assays for influenza: a systematic analysis. Front. Immunol. 6, 161 (2015).","journal-title":"Front. Immunol."},{"key":"1278_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"1278_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562\u2013569 (2020).","journal-title":"Nat. Microbiol."},{"key":"1278_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00527-21","volume":"59","author":"AM Sholukh","year":"2021","unstructured":"Sholukh, A. M. et al. Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays. J. Clin. Microbiol. 59, e0052721 (2021).","journal-title":"J. Clin. Microbiol."},{"key":"1278_CR11","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1885\u20131898 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1278_CR12","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41591-022-01739-w","volume":"28","author":"L Chu","year":"2022","unstructured":"Chu, L. et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat. Med. 28, 1042\u20131049 (2022).","journal-title":"Nat. Med."},{"key":"1278_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71225-1","volume":"10","author":"K Steeds","year":"2020","unstructured":"Steeds, K. et al. Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies. Sci. Rep. 10, 14289 (2020).","journal-title":"Sci. Rep."},{"key":"1278_CR14","doi-asserted-by":"publisher","unstructured":"Bentley, E. M. et al. Cross-neutralisation of novel bombali virus by Ebola virus antibodies and convalescent plasma using an optimised pseudotype-based neutralisation assay. Trop. Med. Infect. Dis. vol. 6 at https:\/\/doi.org\/10.3390\/tropicalmed6030155 (2021).","DOI":"10.3390\/tropicalmed6030155"},{"key":"1278_CR15","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.3390\/v13081579","volume":"13","author":"AT Sampson","year":"2021","unstructured":"Sampson, A. T. et al. Coronavirus pseudotypes for all circulating human coronaviruses for quantification of cross-neutralizing antibody responses. Viruses 13, 1579 (2021).","journal-title":"Viruses"},{"key":"1278_CR16","doi-asserted-by":"publisher","first-page":"110841","DOI":"10.1016\/j.celrep.2022.110841","volume":"39","author":"AS Enriquez","year":"2022","unstructured":"Enriquez, A. S. et al. Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies. Cell Rep. 39, 110841 (2022).","journal-title":"Cell Rep."},{"key":"1278_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0168-1702(99)00070-2","volume":"64","author":"M Ma","year":"1999","unstructured":"Ma, M. et al. Murine leukemia virus pseudotypes of La Crosse and Hantaan Bunyaviruses: a system for analysis of cell tropism. Virus Res. 64, 23\u201332 (1999).","journal-title":"Virus Res."},{"key":"1278_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01069-24","volume":"98","author":"JH Kuhn","year":"2024","unstructured":"Kuhn, J. H. et al. Promotion of order Bunyavirales to class Bunyaviricetes to accommodate a rapidly increasing number of related polyploviricotine viruses. J. Virol. 98, e0106924 (2024).","journal-title":"J. Virol."},{"key":"1278_CR19","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.3390\/v14102139","volume":"14","author":"H Boshra","year":"2022","unstructured":"Boshra, H. An overview of the infectious cycle of bunyaviruses. Viruses 14, 2139 (2022).","journal-title":"Viruses"},{"key":"1278_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.virusres.2004.08.009","volume":"106","author":"HR Jayakar","year":"2004","unstructured":"Jayakar, H. R., Jeetendra, E. & Whitt, M. A. Rhabdovirus assembly and budding. Virus Res. 106, 117\u2013132 (2004).","journal-title":"Virus Res."},{"key":"1278_CR21","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1128\/JVI.78.13.7153-7164.2004","volume":"78","author":"V Sandrin","year":"2004","unstructured":"Sandrin, V., Muriaux, D., Darlix, J.-L. & Cosset, F.-L. Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. J. Virol. 78, 7153\u20137164 (2004).","journal-title":"J. Virol."},{"key":"1278_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-981-99-0113-5_14","volume":"1407","author":"R Chen","year":"2023","unstructured":"Chen, R., Huang, W. & Wang, Y. Pseudotyped virus for bandavirus. Adv. Exp. Med. Biol. 1407, 265\u2013277 (2023).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1278_CR23","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00705-016-2803-1","volume":"161","author":"Y Suda","year":"2016","unstructured":"Suda, Y. et al. Analysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping system. Arch. Virol. 161, 1447\u20131454 (2016).","journal-title":"Arch. Virol."},{"key":"1278_CR24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00705-020-04576-9","volume":"165","author":"AA Vasmehjani","year":"2020","unstructured":"Vasmehjani, A. A. et al. Efficient production of a lentiviral system for displaying Crimean-Congo hemorrhagic fever virus glycoproteins reveals a broad range of cellular susceptibility and neutralization ability. Arch. Virol. 165, 1109\u20131120 (2020).","journal-title":"Arch. Virol."},{"key":"1278_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4142\/jvs.2018.19.2.200","volume":"19","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Packaging of Rift Valley fever virus pseudoviruses and establishment of a neutralization assay method. J. Vet. Sci. 19, 200\u2013206 (2018).","journal-title":"J. Vet. Sci."},{"key":"1278_CR26","doi-asserted-by":"publisher","first-page":"e1004390","DOI":"10.1371\/journal.ppat.1004390","volume":"10","author":"O Shtanko","year":"2014","unstructured":"Shtanko, O., Nikitina, R. A., Altuntas, C. Z., Chepurnov, A. A. & Davey, R. A. Crimean-Congo hemorrhagic fever virus entry into host cells occurs through the multivesicular body and requires ESCRT regulators. PLoS Pathog. 10, e1004390 (2014).","journal-title":"PLoS Pathog."},{"key":"1278_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44210-6","volume":"9","author":"SE Rodriguez","year":"2019","unstructured":"Rodriguez, S. E. et al. Vesicular stomatitis virus-based vaccine protects mice against Crimean-Congo hemorrhagic fever. Sci. Rep. 9, 7755 (2019).","journal-title":"Sci. Rep."},{"key":"1278_CR28","first-page":"534","volume":"13","author":"R Antonelli","year":"2024","unstructured":"Antonelli, R. et al. A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison. F1000Research 13, 534 (2024).","journal-title":"F1000Research"},{"key":"1278_CR29","unstructured":"WHO. Oropouche virus disease. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/oropouche-virus-disease (2024)."},{"key":"1278_CR30","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1080\/21645515.2019.1627820","volume":"15","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus. Hum. Vaccin. Immunother. 15, 2286\u20132294 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1278_CR31","unstructured":"Nichol, S. T. et al. The Bunyaviridae. in Virus Taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses (eds. Fauquet, C. M., Mayo, M. A., Maniloff, J., Desselberger, U. & Ball, L. A.) 695\u2013716 (Elsevier, 2005)."},{"key":"1278_CR32","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","volume":"24","author":"K Spik","year":"2006","unstructured":"Spik, K. et al. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24, 4657\u20134666 (2006).","journal-title":"Vaccine"},{"key":"1278_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008850","volume":"16","author":"N Freitas","year":"2020","unstructured":"Freitas, N. et al. The interplays between Crimean-Congo hemorrhagic fever virus (CCHFV) M segment-encoded accessory proteins and structural proteins promote virus assembly and infectivity. PLoS Pathog. 16, e1008850 (2020).","journal-title":"PLoS Pathog."},{"key":"1278_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct. Target. Ther. 8, 149 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1278_CR35","doi-asserted-by":"publisher","first-page":"e2025642118","DOI":"10.1073\/pnas.2025642118","volume":"118","author":"NS Chapman","year":"2021","unstructured":"Chapman, N. S. et al. Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition. Proc. Natl Acad. Sci. USA 118, e2025642118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1278_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.antiviral.2017.08.014","volume":"146","author":"M Zivcec","year":"2017","unstructured":"Zivcec, M. et al. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus. Antivir. Res. 146, 112\u2013120 (2017).","journal-title":"Antivir. Res."},{"key":"1278_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51108-z","volume":"15","author":"X Ren","year":"2024","unstructured":"Ren, X. et al. A broadly protective antibody targeting glycoprotein Gn inhibits severe fever with thrombocytopenia syndrome virus infection. Nat. Commun. 15, 7009 (2024).","journal-title":"Nat. Commun."},{"key":"1278_CR38","doi-asserted-by":"publisher","unstructured":"Toledo-Teixeira, D. A. et al. MyD88 signalling in B cells and antibody responses during Oropouche virus-induced neurological disease in mice. eBioMedicine 105815, https:\/\/doi.org\/10.1016\/j.ebiom.2025.105815 (2025).","DOI":"10.1016\/j.ebiom.2025.105815"},{"key":"1278_CR39","doi-asserted-by":"publisher","first-page":"1341332","DOI":"10.3389\/fcimb.2024.1341332","volume":"14","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Establishment of two serological methods for detecting IgG and neutralizing antibodies against Crimean-Congo hemorrhagic fever virus glycoprotein. Front. Cell. Infect. Microbiol. 14, 1341332 (2024).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"1278_CR40","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7883\/yoken.JJID.2017.354","volume":"71","author":"Y Suda","year":"2018","unstructured":"Suda, Y. et al. The development of a novel diagnostic assay that utilizes a pseudotyped vesicular stomatitis virus for the detection of neutralizing activity against Crimean-Congo hemorrhagic fever virus. Jpn. J. Infect. Dis. 71, 205\u2013208 (2018).","journal-title":"Jpn. J. Infect. Dis."},{"key":"1278_CR41","doi-asserted-by":"publisher","first-page":"199409","DOI":"10.1016\/j.virusres.2024.199409","volume":"346","author":"S Kempster","year":"2024","unstructured":"Kempster, S. et al. Convalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model. Virus Res. 346, 199409 (2024).","journal-title":"Virus Res."},{"key":"1278_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2018.09.009","volume":"159","author":"MS Mehand","year":"2018","unstructured":"Mehand, M. S., Al-Shorbaji, F., Millett, P. & Murgue, B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antivir. Res. 159, 63\u201367 (2018).","journal-title":"Antivir. Res."},{"key":"1278_CR43","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/infdis\/jiac296","volume":"227","author":"MC Cassetti","year":"2023","unstructured":"Cassetti, M. C. et al. Prototype pathogen approach for vaccine and monoclonal antibody development: a critical component of the NIAID plan for pandemic preparedness. J. Infect. Dis. 227, 1433\u20131441 (2023).","journal-title":"J. Infect. Dis."},{"key":"1278_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","volume":"11","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg. Microbes Infect. 11, 1\u20135 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"1278_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","volume":"29","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44\u201357.e9 (2021).","journal-title":"Cell Host Microbe"},{"key":"1278_CR46","doi-asserted-by":"publisher","first-page":"678570","DOI":"10.3389\/fimmu.2021.678570","volume":"12","author":"G Bullen","year":"2021","unstructured":"Bullen, G. et al. Cross-reactive SARS-CoV-2 neutralizing antibodies from deep mining of early patient responses. Front. Immunol. 12, 678570 (2021).","journal-title":"Front. Immunol."},{"key":"1278_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89957-z","volume":"11","author":"A Miller","year":"2021","unstructured":"Miller, A. et al. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection. Sci. Rep. 11, 10617 (2021).","journal-title":"Sci. Rep."},{"key":"1278_CR48","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3390\/v16121936","volume":"16","author":"P Brangel","year":"2024","unstructured":"Brangel, P. et al. A global collaborative comparison of SARS-CoV-2 antigenicity across 15 laboratories. Viruses 16, 1936 (2024).","journal-title":"Viruses"},{"key":"1278_CR49","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/fvl.15.106","volume":"11","author":"B King","year":"2016","unstructured":"King, B. et al. Technical considerations for the generation of novel pseudotyped viruses. Future Virol. 11, 47\u201359 (2016).","journal-title":"Future Virol."},{"key":"1278_CR50","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41422-023-00917-w","volume":"34","author":"Z-S Xu","year":"2024","unstructured":"Xu, Z.-S. et al. LDLR is an entry receptor for Crimean-Congo hemorrhagic fever virus. Cell Res. 34, 140\u2013150 (2024).","journal-title":"Cell Res."},{"key":"1278_CR51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204706119","volume":"119","author":"MM Schwarz","year":"2022","unstructured":"Schwarz, M. M. et al. Oropouche orthobunyavirus infection is mediated by the cellular host factor Lrp1. Proc. Natl Acad. Sci. USA 119, e2204706119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1278_CR52","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1016\/j.cell.2021.09.001","volume":"184","author":"SS Ganaie","year":"2021","unstructured":"Ganaie, S. S. et al. Lrp1 is a host entry factor for Rift Valley fever virus. Cell 184, 5163\u20135178.e24 (2021).","journal-title":"Cell"},{"key":"1278_CR53","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1128\/JVI.01810-14","volume":"89","author":"GS Mohan","year":"2014","unstructured":"Mohan, G. S. et al. Less is more: Ebola Virus surface glycoprotein expression levels regulate virus production and infectivity. J. Virol. 89, 1205\u20131217 (2014).","journal-title":"J. Virol."},{"key":"1278_CR54","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/S2666-5247(23)00324-5","volume":"5","author":"M Manak","year":"2024","unstructured":"Manak, M. et al. Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis. Lancet Microbe 5, e216\u2013e225 (2024).","journal-title":"Lancet Microbe"},{"key":"1278_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1184362","volume":"14","author":"D Cantoni","year":"2023","unstructured":"Cantoni, D. et al. Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature. Front. Immunol. 14, 1184362 (2023).","journal-title":"Front. Immunol."},{"key":"1278_CR56","first-page":"3858","volume":"42","author":"H Nakabayashi","year":"1982","unstructured":"Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T. & Sato, J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42, 3858\u20133863 (1982).","journal-title":"Cancer Res."},{"key":"1278_CR57","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1046\/j.1365-3083.2002.01015.x","volume":"55","author":"RJ Cox","year":"2002","unstructured":"Cox, R. J., Mykkeltvedt, E., Robertson, J. & Haaheim, L. R. Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scand. J. Immunol. 55, 14\u201323 (2002).","journal-title":"Scand. J. Immunol."},{"key":"1278_CR58","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nbt0997-871","volume":"15","author":"R Zufferey","year":"1997","unstructured":"Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871\u2013875 (1997).","journal-title":"Nat. Biotechnol."},{"key":"1278_CR59","unstructured":"Capecchi, B. et al. Use of pseudotyped particles expressing influenza A\/Viet Nam\/1194\/2004 haemagglutinin in immunological assays. Options for the Control of Influenza VI (2007)."},{"key":"1278_CR60","doi-asserted-by":"publisher","unstructured":"Mattiuzzo, G., Bentley, E. & Marchesin, F. Production of bunyavirus pseudotyped virus. https:\/\/doi.org\/10.17504\/protocols.io.5jyl88nkdl2w\/v1 (2025).","DOI":"10.17504\/protocols.io.5jyl88nkdl2w\/v1"},{"key":"1278_CR61","doi-asserted-by":"publisher","unstructured":"Hierholzer, J. C. & Killington, R. A. Virus isolation and quantitation. Virology Methods Manual 25\u201346. https:\/\/doi.org\/10.1016\/B978-012465330-6\/50003-8 (1996).","DOI":"10.1016\/B978-012465330-6\/50003-8"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01278-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01278-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01278-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T14:03:26Z","timestamp":1762437806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01278-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1278"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01278-8","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. The funding bodies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}